<DOC>
	<DOCNO>NCT03087110</DOCNO>
	<brief_summary>This study investigate safety single dose intravenous infusion cord blood cell cryopreserved birth brother sister child cerebral palsy .</brief_summary>
	<brief_title>Stem Cells Umbilical Blood Infusion CP</brief_title>
	<detailed_description>Cerebral palsy ( CP ) common physical disability childhood , affect 2 per 1000 live birth across world . CP describes permanent non-progressive motor disorder arise damage develop brain . Preclinical study different type stem cell model acute brain injury similar CP show significant functional improvement . The variety stem cell available umbilical cord blood ( UCB ) , ethically uncomplicated source stem cell , lead focus UCB stem cell therapy quick-to-clinic option . Previous study indicate autologous unrelated donor UCBC infusion safe feasible child CP , may lead improved motor functioning , information safety effect match sibling cord blood . Therefore , trial study safety infuse match sibling cord blood cell child cerebral palsy .</detailed_description>
	<mesh_term>Cerebral Palsy</mesh_term>
	<criteria>1 . Diagnosis type CP 2 . CP severity 3 . A record sibling CBU storage TGA accredit private cord blood bank 4 . Ability travel one trial centre 5 . Ability participate assessment 6 . Informed consent parent/guardian 1. presence progressive neurological disease 2. know genetic disorder 3. know brain dysplasia 4. immune system disorder immune deficiency syndrome 5. infectious disease marker show virology screen 6. evidence cord blood unit contamination , few 10^7 cells/kg body mass 7. ventilator support 8. ill health , participant 's medical condition allow safe travel 9. previous cell therapy 10 . Botulinum toxin A within 3 month infusion 11. surgery within 3 month infusion 12. obtain parent/guardian consent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>